Chk1 | Clinical Trials Search

59 results for “Chk1”

Need more precision?

Filter by phase, recruitment status, country, sponsor, age, and study type.

Refine trial search

A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors

17 participants · First posted Apr 12, 2018

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

85 participants · First posted Apr 25, 2023

A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer

107 participants · First posted Jun 14, 2016

Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors

29 participants · First posted Feb 17, 2017

A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer

111 participants · First posted Jul 30, 2014

Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia

32 participants · First posted Jun 6, 2013

A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency

27 participants · First posted Aug 22, 2016

Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

30 participants · First posted Jun 22, 2016

A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects

153 participants · First posted Jun 14, 2016

A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor

14 participants · First posted Mar 11, 2022

Page 1 of 2